Elyse Seltzer, M.D.
Scientific Advisory Board Member
Elyse Seltzer, M.D. is Chief Development Officer at UroGen Pharma, where she led the clinical development of Jelmtyo for the treatment of low-grade upper tract urothelial carcinoma. Prior to joining UroGen, Dr. Seltzer served as Chief Medical Officer of Nabriva Therapeutics where she was responsible for the company’s clinical development of Xenleta (lefamulin) for community-acquired pneumonia. Prior, Dr. Seltzer held leadership roles at GlaxoSmithKline, Tengion, Centocor, and Vicuron. Before joining the pharmaceutical industry, she practiced consultative infectious diseases and HIV care.